Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications
OPEN ACCESS
Loading...
Author / Producer
Date
2024-03
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
OPEN ACCESS
Data
Abstract
Observational studies of osteoporosis medications can provide critical real-world evidence (RWE) that fills knowledge gaps left by clinical trials. However, careful consideration of study design is needed to yield reliable estimates of association. In particular, obtaining valid measurements of exposure to osteoporosis medications from real-world data (RWD) sources is complicated due to different medication classes, formulations, and routes of administration, each with different pharmacology. Extended half-lives of bisphosphonates and extended dosing of denosumab and zoledronic acid require particular attention. In addition, prescribing patterns and medication taking behavior often result in gaps in therapy, switching, and concomitant use of osteoporosis therapies. In this review, we present important considerations and provide specialized guidance for measuring osteoporosis drug exposures in RWD. First, we compare different sources of RWD used for osteoporosis drug studies and provide guidance on identifying osteoporosis medication use in these data sources. Next, we provide an overview of osteoporosis pharmacology and how it can influence decisions on exposure measurement within RWD. Finally, we present considerations for the measurement of osteoporosis medication exposure, adherence, switching, long-term exposures, and drug holidays using RWD. Ultimately, a thorough understanding of the differences in RWD sources and the pharmacology of osteoporosis medications is essential to obtain valid estimates of the relationship between osteoporosis medications and outcomes, such as fractures, but also to improve the critical appraisal of published studies.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
20
Pages / Article No.
101730
Publisher
Elsevier
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Bisphosphonates; Pharmacoepidemiology; Osteoporosis; Drug holiday; Epidemiology; Denosumab
Organisational unit
09633 - Burden, Andrea (ehemalig) / Burden, Andrea (former)
09633 - Burden, Andrea (ehemalig) / Burden, Andrea (former)
09633 - Burden, Andrea (ehemalig) / Burden, Andrea (former)
09633 - Burden, Andrea (ehemalig) / Burden, Andrea (former)